What Happens When
You Stop Ozempic?

Why this question matters

Whether you are taking Ozempic for type 2 diabetes, Wegovy for weight management or Mounjaro, the question of what happens after stopping treatment is one of the most important in GLP-1 therapy. Understanding the evidence helps you make informed decisions about treatment duration and plan for long-term success.

The reality is that GLP-1 receptor agonists treat the underlying biological drivers of obesity — dysregulated appetite hormones, altered satiety signalling and metabolic adaptation — but they do not cure them. When the medication is withdrawn, these biological processes gradually resume, which is why weight regain occurs in most people who stop treatment without a structured maintenance plan.

What the research shows about weight regain

The STEP 1 extension study

The most widely cited evidence comes from the STEP 1 trial extension, published in the journal Diabetes, Obesity and Metabolism. In this study, participants who achieved an average weight loss of 17.3 per cent over 68 weeks on semaglutide 2.4 mg were followed for an additional year after stopping treatment. The key findings were stark:

• Participants regained approximately two-thirds of the weight they had lost within 12 months of discontinuation
• Improvements in cardiometabolic risk factors (blood pressure, lipids, blood glucose) also partially reversed
• The rate of weight regain was fastest in the first 3–6 months after stopping

The STEP 4 withdrawal study

The STEP 4 trial specifically examined the effect of continuing versus withdrawing semaglutide. After 20 weeks of treatment, half the participants switched to placebo whilst the other half continued on semaglutide for an additional 48 weeks. Those who switched to placebo regained an average of 6.9 per cent of body weight, whilst those who continued lost a further 7.9 per cent. This demonstrated clearly that ongoing treatment is needed to maintain weight loss.

Tirzepatide data (SURMOUNT-4)

Similar patterns have been observed with tirzepatide. The SURMOUNT-4 trial showed that patients who switched from tirzepatide to placebo after 36 weeks regained approximately half of their weight loss over the following 52 weeks, whereas those who continued treatment maintained their results.

What happens to your body when you stop

Understanding the physiological changes that occur after discontinuation can help you prepare:

Weeks 1–2: appetite returns

The appetite-suppressing effect of semaglutide and tirzepatide diminishes rapidly. Most patients notice a significant increase in hunger within 1–2 weeks of their last injection. Food cravings, which had been substantially reduced during treatment, typically return. The sensation of early satiety (feeling full quickly) fades as gastric emptying speeds return to baseline.

Weeks 2–8: metabolic adjustment

The metabolic rate, which may have slowed slightly during active weight loss, does not immediately recover. This creates a temporary mismatch between increased appetite and unchanged metabolic rate, which favours weight regain. Blood glucose levels may begin to rise, particularly in patients with type 2 diabetes.

Months 2–6: the critical period

This is when the most rapid weight regain typically occurs. Without the medication's appetite control, patients must rely entirely on behavioural strategies to manage calorie intake. The biological drive to regain weight is at its strongest during this period, as the body's hormonal systems work to restore previous weight set points.

Months 6–12 and beyond

Weight regain generally slows after 6 months but may continue at a lower rate. Most patients stabilise at a weight that is higher than their lowest point on medication but lower than their pre-treatment weight, provided they maintain lifestyle changes. However, some patients return to or even exceed their starting weight.

Tapering strategies

Neither Novo Nordisk (manufacturer of Ozempic and Wegovy) nor Eli Lilly (Mounjaro) officially recommend tapering before discontinuation. The medications can be stopped abruptly without withdrawal symptoms in the traditional sense. However, many UK clinicians advocate for a gradual dose reduction to ease the transition. Potential approaches include:

Gradual dose reduction

• Step-down over 8–12 weeks: Reduce from your maintenance dose to the next lower dose every 4 weeks until you reach the lowest available dose, then stop
• Example for Wegovy: 2.4 mg → 1.7 mg → 1.0 mg → 0.5 mg → 0.25 mg → stop
• Example for Mounjaro: 15 mg → 10 mg → 7.5 mg → 5 mg → 2.5 mg → stop

Extended interval approach

• Maintain your current dose but extend the interval between injections: weekly → every 10 days → every 2 weeks → stop
• This is not formally studied but some clinicians find it helpful for patients

How to maintain weight loss after stopping

Whilst weight regain is common, it is not inevitable at full scale. Research and clinical experience suggest several strategies that can help preserve a meaningful portion of weight loss:

1. Establish habits during treatment

The period on GLP-1 medication is an opportunity to build sustainable eating and exercise habits. Use the reduced appetite to establish portion control, regular meal patterns and increased physical activity. These habits become your foundation after stopping. See our diet guide for GLP-1 medication for detailed nutritional guidance.

2. Prioritise protein and resistance training

Preserving lean muscle mass is critical for maintaining metabolic rate. Continue consuming 1.2–1.5 g of protein per kilogram of body weight daily and engage in resistance training at least 2–3 times per week. Muscle tissue burns more calories at rest than fat tissue, so preserving it helps prevent weight regain.

3. Regular self-monitoring

• Weigh yourself weekly (same day, same time, same conditions)
• Track food intake for at least the first 3 months after stopping
• Set a personal action threshold (e.g. if weight increases by 3 kg, implement specific strategies)

4. Structured behavioural support

Access to a dietitian, health coach or structured programme (such as those offered by UK weight loss clinics) significantly improves maintenance outcomes. Behavioural strategies for managing hunger, emotional eating and food choices become essential once the medication's appetite control is no longer present.

5. Consider maintenance dosing

Emerging evidence and clinical practice suggest that some patients may benefit from long-term, lower-dose maintenance therapy rather than complete discontinuation. This approach is increasingly supported by NICE's recognition of obesity as a chronic condition. Discuss this option with your clinician.

When stopping may be appropriate

There are several situations where stopping GLP-1 medication may be considered:

• Intolerable side effects that do not resolve with dose adjustment. See our side effects guide
• Planning pregnancy: GLP-1 medications should be stopped at least 2 months before conceiving
• Reaching treatment goals with a robust maintenance plan in place
• Financial constraints: Private prescriptions can be costly long-term
• Transition to surgery: Some patients stop medication before bariatric surgery
• Clinical recommendation: If the medication is not producing adequate results after 6 months at maximum tolerated dose

Frequently asked questions

Will I regain all the weight if I stop Ozempic?

Not necessarily all of it, but studies indicate that most people regain a substantial portion. The STEP 1 extension found that participants regained about two-thirds of lost weight within a year. However, those who maintain strong dietary habits, regular exercise and behavioural strategies tend to keep off more weight than those who do not.

Is it safe to stop Ozempic suddenly?

Yes, semaglutide can be stopped abruptly without dangerous withdrawal effects. However, if you take it for type 2 diabetes, your blood glucose levels are likely to rise, so your clinician may need to adjust other medications. The main concern is weight regain rather than acute safety risks.

Can I go back on GLP-1 medication if I regain weight?

Yes, restarting GLP-1 medication is possible and is a recognised clinical strategy. If you regain significant weight after stopping, discuss restarting with your prescriber. You will typically need to go through the dose-escalation process again from the starting dose.

Does the weight regain apply to Mounjaro as well?

Yes. The SURMOUNT-4 trial demonstrated similar patterns of weight regain after stopping tirzepatide. The underlying principle is the same: GLP-1-based medications treat the symptoms of obesity whilst active, and the condition tends to recur when treatment stops.